A randomised, double- blind, 2 way cross-over study to determine 24-hour FEV1-time profile of inhaled tiotropium, delivered via the Respimat inhaler, after 4 weeks of once daily [5 Mcg in the evening (2 actuations of 2.5 Mcg)] or twice daily [2.5 Mcg in the morning and evening (2 actuations of 1.25 Mcg)] administration in patients with moderate persistent asthma.

Trial Profile

A randomised, double- blind, 2 way cross-over study to determine 24-hour FEV1-time profile of inhaled tiotropium, delivered via the Respimat inhaler, after 4 weeks of once daily [5 Mcg in the evening (2 actuations of 2.5 Mcg)] or twice daily [2.5 Mcg in the morning and evening (2 actuations of 1.25 Mcg)] administration in patients with moderate persistent asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2018

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Asthma
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 01 Apr 2018 Results of pooled data from vitro compared with nine clinical trial assessing PK exposure to tiotropium in preschool children with persistent asthmatic symptoms (using test VHC), were published in the Respiratory Medicine.
    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top